Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CMND-100 · MEAI

Small molecule · developed by Clearmind Medicine

Phase 1/2 Most advanced trial

CMND Developer

1 Registered trials

What is CMND-100?

CMND-100 is a gelatin capsule formulation of 5-methoxy-2-aminoindane (MEAI), a psychoactive compound of the aminoindane class, given at 20 or 60 mg with stabilizing excipients. It is studied in alcohol use disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MEAI
Drug type: Small molecule
Therapy area: Psychiatry
Developer: Clearmind Medicine Inc. (CMND)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: AD8S15863A

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05913752	Phase 1/2	Alcohol Use Disorder	Recruiting	CMND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alcohol Use Disorder

Sources

ClinicalTrials.gov NCT05913752

Updated Oct 11, 2026. Something wrong or missing? Report it on the CMND page.

Follow CMND, the company behind CMND-100

See CMND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CMND catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z